Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Tempus And JW Pharmaceutical Partner for Data-Based Early R&D
Details : The collaboration aims to leverage both real-world data (RWD) and biological modeling to support efficient hypothesis generation and rapid validation in early therapeutic research in oncology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
October 28, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Oncocross
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Oncocross Expands Collaboration with JW Pharmaceutical on AI Drug Development
Details : The companies will identify and verify development possibilities for new indications for first-in-class drug pipeline that JW Pharmaceutical is developing in anticancer and regenerative medicine.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 27, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Oncocross
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : CWP291
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
JW Pharmaceutical to Repurpose Targeted Oncology Drug as COVID-19 Therapy
Details : CWP291 is a Wnt/beta-catenin inhibitor that is under development as a first-in-class treatment for acute myeloid leukemia, multiple myeloma and stomach cancer.
Product Name : CWP291
Product Type : Small molecule
Upfront Cash : Not Applicable
June 17, 2020
Lead Product(s) : CWP291
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Reset All
